• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

Harnessing the Tumor Microenvironment for Enhanced Cancer Treatment

by MM360 Staff | Jun 1, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

NLA 2025: Exploring the Evidence Behind Omega-3 Fatty Acids for Cardiovascular Risk

by MM360 Staff | Jun 1, 2025 | Myeloma News

Source: Pharmacy Times articles Frank Qian, MD, MPH, discusses the clinical indications, dosing strategies, and cardiovascular outcomes data for prescription omega-3 fatty acids, including the ongoing debate about EPA vs EPA-DHA formulations and the implications of...

From Resistance to Response: The Microbiome’s Role in Optimizing Cancer Therapy

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

NLA 2025: GLP-1 Therapies May Impact Cardiovascular and Renal Health Independent of Weight Loss

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles GLP-1 receptor agonists, including semaglutide and tirzepatide, significantly reduce cardiometabolic risk factors such as dyslipidemia, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, obstructive sleep apnea, chronic...

NLA 2025: Novel Therapeutic Approaches Show Promise for Targeted Reduction of Lp(a) in Patients With ASCVD

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles At the 2025 National Lipid Association (NLA) Scientific Sessions, Marlys L. Koschinsky, PhD, FNLA, discusses the role of Lp(a) in cardiovascular risk and the emerging therapies designed to target and lower Lp(a) levels. Read...

ESR1, PIK3CA, and Beyond: Precision Therapy Advances in HR+ Breast Cancer

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More
« Older Entries

Recent Content

  • Harnessing the Tumor Microenvironment for Enhanced Cancer Treatment
  • NLA 2025: Exploring the Evidence Behind Omega-3 Fatty Acids for Cardiovascular Risk
  • From Resistance to Response: The Microbiome’s Role in Optimizing Cancer Therapy
  • NLA 2025: GLP-1 Therapies May Impact Cardiovascular and Renal Health Independent of Weight Loss
  • Day 2: Top Takeaways From ASCO25
  • NLA 2025: Novel Therapeutic Approaches Show Promise for Targeted Reduction of Lp(a) in Patients With ASCVD
  • ESR1, PIK3CA, and Beyond: Precision Therapy Advances in HR+ Breast Cancer
  • Updated ASCO-NCODA MIP Standards Emphasize Health Equity, Patient-Centered Care, and Integrated Workflows in Oral Oncolytic Management
  • A simple genomic score to predict progression of multiple myeloma
  • IVIG Increases Platelet Counts in Pregnant Patients With Severe Thrombocytopenia, With Identifiable Aspects of Response
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT